Stockreport

Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Pa...

Syros Pharmaceuticals, Inc.  (SYRS) 
Last syros pharmaceuticals, inc. earnings: 3/5 06:57 am Check Earnings Report
US:NASDAQ Investor Relations: ir.syros.com
PDF Cohort Added to Ongoing Phase 2 Trial of SY-1425 to Evaluate Safety and Efficacy of the Combination in Biomarker-Selected Relapsed or Refractory AML or H [Read more]